```
     FILE 'REGISTRY' ENTERED AT 13:41:40 ON 01 MAR 2010
                EXP TRIACETYLURIDINE/CN
                EXP TRIACETYL URIDINE/CN
                EXP 2,3,5-TRIACETYL URIDINE/CN
                EXP ETHOXCARBONYLURIDINE\
                EXP ETHOXCARBONYLURIDINE/CN
                EXP PERACETYLURIDINE/CN
                EXP PERACETYL URIDINE/CN

     FILE 'HCAPLUS' ENTERED AT 13:43:26 ON 01 MAR 2010
L1           56 S TRIACETYLURIDINE OR (TRIACETYL URIDINE) OR TRIACETYLCYTIDINE
L2           56 S TRIACETYLURIDINE OR (TRIACETYL URIDINE) OR TRIACETYLCYTIDINE
L3           35 S L2 AND (PY<1993 OR AY<1993 OR PRY<1993)

     FILE 'REGISTRY' ENTERED AT 14:39:14 ON 01 MAR 2010
L4            1 S 4105-38-8/RN
L5            1 S 5040-18-6/RN

     FILE 'HCAPLUS' ENTERED AT 14:39:49 ON 01 MAR 2010
L6           52 S L4/THU
L7           52 S L4/THU OR L5/THU
L8            9 S L7 AND (PY<1993 OR AY<1993 OR PRY<1993)
```

```
=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.22       0.22

FILE 'REGISTRY' ENTERED AT 13:41:40 ON 01 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 FEB 2010  HIGHEST RN 1207513-60-7
DICTIONARY FILE UPDATES:  28 FEB 2010  HIGHEST RN 1207513-60-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp triacetyluridine/cn
E1            1     TRIACETYLTRIBENZYLHEXAAZAISOWURTZITANE/CN
E2            1     TRIACETYLUMBROSIN/CN
E3            0 --> TRIACETYLURIDINE/CN
E4            1     TRIACETYLUSKUDARAMINE/CN
E5            1     TRIACETYLZYGADENINE/CN
E6            1     TRIACID ALIZARINE GREEN G/CN
E7            1     TRIACID AMARANTH A/CN
E8            1     TRIACID AMIDONAPHTHOL RED 6B/CN
E9            1     TRIACID AMIDONAPHTHOL RED G/CN
E10           1     TRIACID AZOEOSINE E/CN
E11           1     TRIACID BENGAL ROSE B/CN
E12           1     TRIACID BLUE AE/CN

=> exp triacetyl uridine/cn
E1            1     TRIACETYL THIOZAMIN/CN
E2            1     TRIACETYL TRICIN/CN
E3            0 --> TRIACETYL URIDINE/CN
E4            1     TRIACETYL-B-DAUNOSAMINE/CN
E5            1     TRIACETYL-Ψ-LYCORINE/CN
E6            1     TRIACETYL-4-AMINOPHENOL/CN
E7            1     TRIACETYL-4-EPISHIKIMIC ACID METHYL ESTER/CN
E8            1     TRIACETYL-4-PYRIDOXYL-4,5,6,7-TETRAHYDRO-3H-IMIDAZO(4,5-C)PY
                    RIDINE/CN
E9            1     TRIACETYL-5-FLUOROURIDINE/CN
E10           1     TRIACETYL-6-PURINYLHISTAMINE/CN
E11           1     TRIACETYL-CYANURIC ACID/CN
E12           1     TRIACETYL-D-GALACTAL/CN

=> exp 2,3,5-triacetyl uridine/cn
E1            1     2,3,5-TRIACETOXYBIPHENYL/CN
```

```
E2            1     2,3,5-TRIACETOXYPYRIDINE/CN
E3            0 --> 2,3,5-TRIACETYL URIDINE/CN
E4            1     2,3,5-TRIACETYL-D-RIBOFURANOSYL CHLORIDE/CN
E5            1     2,3,5-TRIAMINO-1,4-NAPHTHOQUINONE/CN
E6            1     2,3,5-TRIAMINO-4,6-DIMETHYLPYRIDINE/CN
E7            1     2,3,5-TRIAMINO-4,6-DIMETHYLPYRIDINE BISMETHANESULFONATE/CN
E8            1     2,3,5-TRIAMINOBENZALDEHYDE/CN
E9            1     2,3,5-TRIAMINOBENZONITRILE/CN
E10           1     2,3,5-TRIAMINOBROMOBENZENE/CN
E11           1     2,3,5-TRIAMINOCHLOROBENZENE/CN
E12           1     2,3,5-TRIAZA-1,4-DIBORAHEPTANE-1,1,4-TRIAMINE, 6-METHYL-2-(1
                    -METHYLETHENYL)-N1,N1,N1',N1',3,5-HEXAKIS(1-METHYLETHYL)-/CN

=> exp 2',3',5'-triacetyl uridine/cn
MISMATCHED QUOTE IN EXPAND TERM
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> exp ethoxcarbonyluridine\
E1            1     ETHOXAZORUTIN/BI
E2            1     ETHOXAZORUTOSIDE/BI
E3            0 --> ETHOXCARBONYLURIDINE\/BI
E4            2     ETHOXENE/BI
E5            1     ETHOXID/BI
E6          453     ETHOXIDE/BI
E7            1     ETHOXIDEBIS/BI
E8            2     ETHOXIDES/BI
E9            1     ETHOXIDINE/BI
E10           1     ETHOXIDO/BI
E11           1     ETHOXIDOL/BI
E12           4     ETHOXIM/BI

=> exp ethoxcarbonyluridine/cn
E1            1     ETHOXAZORUTIN/CN
E2            1     ETHOXAZORUTOSIDE/CN
E3            0 --> ETHOXCARBONYLURIDINE/CN
E4            1     ETHOXENE/CN
E5            2     ETHOXIDE/CN
E6            1     ETHOXIDE (PHARMACEUTICAL)/CN
E7            1     ETHOXIDE ANION/CN
E8            1     ETHOXIDE ION/CN
E9            1     ETHOXIDE, N,N'-O-PHENYLENEBIS(SALICYLIDENEAMINATO)MANGANESE
                    COMPLEX/CN
E10           1     ETHOXIDE-1,1-D2/CN
E11           1     ETHOXIDINE/CN
E12           1     ETHOXIDOL/CN

=> exp peracetyluridine/cn
E1            1     PERACETYLSHATAVARIN IV/CN
E2            1     PERACETYLTEULAMIOSIDE/CN
E3            0 --> PERACETYLURIDINE/CN
E4            1     PERACID AC/CN
E5            1     PERACID HYDROLASE/CN
E6            1     PERACIT 4018F/CN
E7            1     PERACIT 4439X1/CN
E8            1     PERACIT 4536K/CN
E9            1     PERACIT 5030A/CN
E10           1     PERACIT 5042/CN
E11           1     PERACIT 5044/CN
E12           1     PERACIT 5046/CN
```

```
=> exp peracetyl uridine/cn
E1            1     PERACETYL RADICAL/CN
E2            1     PERACETYL TIBETICOSIDE A/CN
E3            0 --> PERACETYL URIDINE/CN
E4            1     PERACETYL-D-ARABINOSE/CN
E5            1     PERACETYL-D-GALACTOSE DIETHYL DITHIOACETAL/CN
E6            1     PERACETYL-D-GLUCOSE/CN
E7            1     PERACETYL-D-MALTOHEPTAOSE/CN
E8            1     PERACETYLARDISIOSIDE A/CN
E9            1     PERACETYLARDISIOSIDE B/CN
E10           1     PERACETYLATED A-CYCLODEXTRIN/CN
E11           1     PERACETYLATED B-CYCLODEXTRIN/CN
E12           1     PERACETYLATED Γ-CYCLODEXTRIN/CN

=> file hcaplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   1.47       1.69

FILE 'HCAPLUS' ENTERED AT 13:43:26 ON 01 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 Mar 2010  VOL 152 ISS 10
FILE LAST UPDATED: 28 Feb 2010  (20100228/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Dec 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s triacetyluridine or (triacetyl uridine) or triacetylcytidine or (triacetyl
cytidine) or ethoxycarbonyluridine or (ethoxyarbonyl uridine)
          42 TRIACETYLURIDINE
        3450 TRIACETYL
       30137 URIDINE
           0 TRIACETYL URIDINE
             (TRIACETYL(W)URIDINE)
          13 TRIACETYLCYTIDINE
        3450 TRIACETYL
       14671 CYTIDINE
```

```
             1 TRIACETYL CYTIDINE
               (TRIACETYL(W)CYTIDINE)
             3 ETHOXYCARBONYLURIDINE
             0 ETHOXYARBONYL
         30137 URIDINE
             0 ETHOXYARBONYL URIDINE
               (ETHOXYARBONYL(W)URIDINE)
L1          56 TRIACETYLURIDINE OR (TRIACETYL URIDINE) OR TRIACETYLCYTIDINE OR
               (TRIACETYL CYTIDINE) OR ETHOXYCARBONYLURIDINE OR (ETHOXYARBONYL
               URIDINE)

=> s triacetyluridine or (triacetyl uridine) or triacetylcytidine or (triacetyl
cytidine) or ethoxycarbonyluridine or (ethoxycarbonyl uridine)
            42 TRIACETYLURIDINE
          3450 TRIACETYL
         30137 URIDINE
             0 TRIACETYL URIDINE
               (TRIACETYL(W)URIDINE)
            13 TRIACETYLCYTIDINE
          3450 TRIACETYL
         14671 CYTIDINE
             1 TRIACETYL CYTIDINE
               (TRIACETYL(W)CYTIDINE)
             3 ETHOXYCARBONYLURIDINE
         13146 ETHOXYCARBONYL
         30137 URIDINE
             0 ETHOXYCARBONYL URIDINE
               (ETHOXYCARBONYL(W)URIDINE)
L2          56 TRIACETYLURIDINE OR (TRIACETYL URIDINE) OR TRIACETYLCYTIDINE OR
               (TRIACETYL CYTIDINE) OR ETHOXYCARBONYLURIDINE OR (ETHOXYCARBONYL
                URIDINE)

=> s l2 and (PY<1993 or AY<1993 or PRY<1993)
      14944658 PY<1993
       2636069 AY<1993
       2076698 PRY<1993
L3          35 L2 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> d l3 1-35 ti abs bib

L3   ANSWER 1 OF 35  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Compositions of chemotherapeutic agent or antiviral agent with acylated
     pyrimidine nucleosides
AB   The subject invention discloses compds., compns. and methods for treatment
     and prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Thus, biol activity of 5-fluorouracil is reported.
AN   1998:236253  HCAPLUS <<LOGINID::20100301>>
DN   128:266247
OREF 128:52559a,52562a
TI   Compositions of chemotherapeutic agent or antiviral agent with acylated
     pyrimidine nucleosides
IN   Von Borstel, Reid W.; Bamat, Michael K.
PA   Pro-Neuron, Inc., USA
SO   U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 13
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5736531	A	19980407	US 1993-176485	19931230	<--
	EP 712629	A1	19960522	EP 1995-203050	19881027	<--
	EP 712629	B1	20030618			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	JP 10001436	A	19980106	JP 1997-36734	19881027	<--
	JP 3474073	B2	20031208			
	JP 2001192335	A	20010717	JP 2000-379524	19881027	<--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625	<--
	CA 2111571	C	20050823			
	CA 2504078	A1	19930121	CA 1992-2504078	19920625	<--
	CA 2504078	C	20070828			
	ES 2160579	T3	20011116	ES 1992-914215	19920625	<--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703	<--
	IN 175688	A1	19950812	IN 1992-CA473	19920706	<--
	US 5246708	A	19930921	US 1992-911379	19920713	<--
	US 5470838	A	19951128	US 1992-997657	19921230	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	US 6020320	A	20000201	US 1993-153163	19931117	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	US 5770582	A	19980623	US 1995-419767	19950410	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6054441	A	20000425	US 1995-463790	19950605	<--
	US 6060459	A	20000509	US 1995-465016	19950605	<--
	US 7307166	B1	20071211	US 1995-463771	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 5968914	A	19991019	US 1995-472210	19950607	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	US 6348451	B1	20020219	US 1995-478736	19950607	<--
	US 6919320	B1	20050719	US 1995-473331	19950607	<--
	US 7166581	B1	20070123	US 1995-473330	19950607	<--
	US 20010025032	A1	20010927	US 1999-249790	19990216	<--
	US 6344447	B2	20020205			
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 6743782	B1	20040601	US 2000-494242	20000131	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040192635	A1	20040930	US 2004-824501	20040415	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115923	B2	19871028	<--		
	US 1987-115929	B2	19871028	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-487984	B2	19900205	<--		
	US 1991-724340	B2	19910705	<--		
	US 1992-903107	B2	19920625	<--		
	US 1993-61381	B2	19930514			
	US 1988-186031	B2	19880425	<--		
	EP 1988-910239	A3	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	US 1989-341925	B1	19890421	<--		
	US 1990-533933	B1	19900605	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-653882	B2	19910208	<--		

```
     US 1991-737913       B3    19910729  <--
     CA 1992-2111571      A3    19920625  <--
     IN 1992-CA473        A1    19920706  <--
     US 1992-911379       A3    19920713  <--
     US 1992-925931       B2    19920807  <--
     US 1992-958598       B3    19921007  <--
     US 1992-987730       B2    19921208  <--
     US 1992-997657       A3    19921230  <--
     US 1993-96407        B1    19930726
     US 1993-98884        B1    19930729
     US 1993-153163       A1    19931117
     US 1993-158799       B2    19931201
     US 1993-176485       A2    19931230
     US 1994-266897       B3    19940701
     US 1994-289214       A3    19940812
     US 1995-419767       A3    19950410
     US 1995-463740       A1    19950605
     US 1995-472210       A1    19950607
     AU 1995-29150        A3    19950630
     AU 1999-52624        A3    19991001
     US 2000-494242       A3    20000131
     AU 2002-320811       A3    20021223
     JP 2005-380457       A3    20051228
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS   MARPAT 128:266247
OSC.G   13    THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT  34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 2 OF 35  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Methods of reducing toxicity of chemotherapeutic and antiviral agents with
     acylated non-methylated pyrimidine nucleosides
AB   Compds., compns. and methods are disclosed for the treatment and
     prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Oral administration of triacetyluridine
     ameliorated the hematol. toxicity of 5-fluorouracil.
     Triacetyluridine and uridine increased the therapeutic index of
     5-fluorouracil in tumor-bearing mice.  Amelioration of the adverse effects
     of e.g. AZT is also described.
AN   1997:141015  HCAPLUS <<LOGINID::20100301>>
DN   126:139905
OREF 126:26891a
TI   Methods of reducing toxicity of chemotherapeutic and antiviral agents with
     acylated non-methylated pyrimidine nucleosides
IN   Vonborstel, Reid W.; Bamat, Michael K.
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 142 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9640165          A1     19961219    WO 1996-US10067        19960606
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
             ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
             SE, SG
```

```
        RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
            IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
     IN 177670          A1    19970215    IN 1994-CA701          19940902 <--
     US 5968914         A     19991019    US 1995-472210         19950607 <--
     AU 9661114         A     19961230    AU 1996-61114          19960606
     AU 724805          B2    20000928
     EP 831849          A1    19980401    EP 1996-918461         19960606
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI
     JP 10511689        T     19981110    JP 1997-502184         19960606
     AU 9952624         A     19991202    AU 1999-52624          19991001
     AU 2002320811      A1    20030403    AU 2002-320811         20021223
     AU 2005232288      A1    20051201    AU 2005-232288         20051110
PRAI US 1995-472210     A     19950607
     US 1987-115923     B2    19871028  <--
     US 1987-115929     B2    19871028  <--
     US 1989-438493     B2    19890627  <--
     US 1990-487984     B2    19900205  <--
     US 1991-724340     B2    19910705  <--
     US 1992-903107     B2    19920625  <--
     IN 1992-CA473      A1    19920706  <--
     US 1993-61381      B2    19930514
     US 1993-176485     A2    19931230
     AU 1995-29150      A3    19950630
     WO 1996-US10067    W     19960606
     AU 1999-52624      A3    19991001
     AU 2002-320811     A3    20021223
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 3 OF 35  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Pyrimidine nucleotide precursors for treatment of systemic inflammation
     and inflammatory hepatitis
AB   Pyrimidine nucleotide precursors, including acyl derivs. of cytidine,
     uridine, and orotate, and uridine phosphorylase inhibitors, and their use
     in enhancing resistance to sepsis or systemic inflammation, are disclosed.
     Triacetyluridine improved survival of mice treated with a LD of
     Salmonella typhimurium endotoxin, reduced endotoxin-caused tissue damage,
     reduced mortality in viral hepatitis in mice, and improved recovery from
     ethanol intoxication.
AN   1996:205056  HCAPLUS <<LOGINID::20100301>>
DN   124:250921
OREF 124:46221a,46224a
TI   Pyrimidine nucleotide precursors for treatment of systemic inflammation
     and inflammatory hepatitis
IN   Von Borstel, Reid W.; Bamat, Michael K.; Hiltbrand, Bradley M.
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 95 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9601115          A1     19960118    WO 1995-US8259         19950630
          W:  AU, CA, CN, JP, KR, MX
          RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     IN 177670           A1     19970215    IN 1994-CA701          19940902 <--
     US 5691320          A      19971125    US 1995-465454         19950605 <--
```

```
     US 6232298           B1    20010515    US 1995-479519          19950607 <--
     CA 2193967           A1    19960118    CA 1995-2193967         19950630
     CA 2193967           C     20070911
     AU 9529150           A     19960125    AU 1995-29150           19950630
     AU 712679            B2    19991111
     EP 768883            A1    19970423    EP 1995-924764          19950630
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     CN 1156409           A     19970806    CN 1995-194806          19950630
     JP 10505578          T     19980602    JP 1996-503935          19950630
     JP 4408450           B2    20100203
     CN 101066276         A     20071107    CN 2006-10105555        19950630
     AU 9952624           A     19991202    AU 1999-52624           19991001
     AU 2002320811        A1    20030403    AU 2002-320811          20021223
     US 20030212036       A1    20031113    US 2003-421831          20030424
     US 20040033981       A1    20040219    US 2003-601863          20030624 <--
     US 20040220134       A1    20041104    US 2004-855835          20040528 <--
     AU 2005232281        A1    20051201    AU 2005-232281          20051110
     AU 2005232286        A1    20051201    AU 2005-232286          20051110
     AU 2005232288        A1    20051201    AU 2005-232288          20051110
     JP 2008007525        A     20080117    JP 2007-250303          20070926
PRAI US 1994-266897       A     19940701
     US 1987-115929       B2    19871028  <--
     US 1989-438493       B2    19890627  <--
     US 1990-438493       B2    19900626  <--
     IN 1992-CA473        A1    19920706  <--
     US 1992-987730       B2    19921208  <--
     US 1993-158799       B2    19931201
     US 1995-463740       A1    19950605
     US 1995-479519       A1    19950607
     AU 1995-29150        A3    19950630
     CN 1995-194806       A3    19950630
     JP 1996-503935       A3    19950630
     WO 1995-US8259       W     19950630
     AU 1999-52624        A3    19991001
     US 2000-702876       A3    20001101
     AU 2002-320811       A3    20021223
OSC.G   8     THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 4 OF 35  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Acylated pyrimidine nucleosides for treatment of toxicity from
     chemotherapeutic and antiviral agents
AB   The subject invention discloses compds., compns. and methods for treatment
     and prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Oral administration of triacetyluridine
     ameliorated the hematol. toxicity of 5-fluorouracil.  Effects of other
     derivs. are also presented.  Synthesis of ethoxycarbonyluridine
     is included.
AN   1995:756200  HCAPLUS <<LOGINID::20100301>>
DN   123:160865
OREF 123:28387a
TI   Acylated pyrimidine nucleosides for treatment of toxicity from
     chemotherapeutic and antiviral agents
IN   Von Borstel, Reid Warren; Bamat, Michael Kevin
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 143 pp.
     CODEN: PIXXD2
```

DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230	
	W: AU, CA, JP, KR					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	AU 9460812	A	19941212	AU 1994-60812	19931230	
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
PRAI	US 1993-61381	A	19930514			
	IN 1992-CA473	A1	19920706	<--		
	WO 1993-US12689	W	19931230			
	AU 1995-29150	A3	19950630			
	AU 1999-52624	A3	19991001			
	AU 2002-320811	A3	20021223			

OS MARPAT 123:160865
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
AB Pyrimidine nucleotide precursors including acyl derivs. of cytidine, uridine, and orotate, and uridine phosphorylase inhibitors, and their use in enhancing resistance to sepsis or systemic inflammation and treating or preventing inflammatory hepatitis are disclosed. Triacetyluridine and uridine improved survival of mice treated with killed Escherichia coli.
AN 1994:549080 HCAPLUS <<LOGINID::20100301>>
DN 121:149080
OREF 121:26721a,26724a
TI Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
IN Von Borstel, Reid Warren; Bamat, Michael Kevin; Hiltbrand, Bradley M.
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9413687	A1	19940623	WO 1993-US11531	19931201	<--
	W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, VN					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	CA 2150940	A1	19940623	CA 1993-2150940	19931201	<--
	CA 2150940	C	20070821			
	CA 2588495	A1	19940623	CA 1993-2588495	19931201	<--
	CA 2588495	C	20091117			
	AU 9457305	A	19940704	AU 1994-57305	19931201	<--
	EP 679160	A1	19951102	EP 1994-903322	19931201	<--
	EP 679160	B1	20041117			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					

```
     JP 08503699           T     19960423    JP 1994-510442          19931201 <--
     AT 282627             T     20041215    AT 1994-903322          19931201 <--
     EP 1486210            A1    20041215    EP 2004-20415           19931201 <--
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE
     PT 679160             E     20050228    PT 1994-903322          19931201 <--
     ES 2229212            T3    20050416    ES 1994-903322          19931201 <--
     IL 107900             A     19991222    IL 1993-107900          19931206 <--
     CN 1095268            A     19941123    CN 1993-121700          19931207 <--
     CN 1089239            C     20020821
     ZA 9309208            A     19940808    ZA 1993-9208            19931208 <--
     IN 177670             A1    19970215    IN 1994-CA701           19940902 <--
     US 5691320            A     19971125    US 1995-465454          19950605 <--
     US 6232298            B1    20010515    US 1995-479519          19950607 <--
     HK 1004484            A1    20050422    HK 1998-103632          19980429 <--
     AU 9878813            A     19981008    AU 1998-78813           19980805 <--
     AU 732120             B2    20010412
     AU 9952624            A     19991202    AU 1999-52624           19991001
     CN 1309970            A     20010829    CN 2000-134481          20001129 <--
     CN 1211089            C     20050720
     AU 2002320811         A1    20030403    AU 2002-320811          20021223
     US 20040033981        A1    20040219    US 2003-601863          20030624 <--
     US 20040220134        A1    20041104    US 2004-855835          20040528 <--
     JP 2005162757         A     20050623    JP 2004-348587          20041201 <--
     AU 2005232288         A1    20051201    AU 2005-232288          20051110
     JP 2007332144         A     20071227    JP 2007-177101          20070705 <--
PRAI US 1992-987730        A     19921208  <--
     US 1993-158799              19931201
     US 1987-115929        B2    19871028  <--
     US 1989-438493        B2    19890627  <--
     US 1990-438493        B2    19900626  <--
     IN 1992-CA473         A1    19920706  <--
     CA 1993-2150940       A3    19931201
     EP 1994-903322        A3    19931201
     JP 1994-510442        A3    19931201
     WO 1993-US11531       W     19931201
     CN 1993-121700        A3    19931207
     US 1994-266897        B3    19940701
     US 1995-463740        A1    19950605
     AU 1995-29150         A3    19950630
     AU 1999-52624         A3    19991001
     AU 2002-320811        A3    20021223
OS   MARPAT 121:149080
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 6 OF 35  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Treatment of chemotherapeutic agent and antiviral agent toxicity with
     acylated pyrimidine nucleosides
AB   The toxicity of antiviral and antineoplastic agents, resulting from their
     damage to the hematopoietic system or mucosal tissue, is prevented or
     treated with acylated derivs. of nonmethylated pyrimidine nucleosides.
     These derivs. may themselves be antineoplastic, antiviral, or antimalarial
     agents; they may be administered together with inhibitors of uridine
     phosphorylase, of cytidine deaminase, or of nucleotide transport.  Thus,
     oral administration of triacetyluridine (500 mg/kg 8 times in 2
     days) rescued mice from the hematol. toxicity of 5-fluorouracil (150 mg/kg
     i.p.), as shown by leukocyte and platelet counts.
AN   1993:205218  HCAPLUS <<LOGINID::20100301>>
DN   118:205218
OREF 118:35053a,35056a
```

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
IN Von Borstel, Reid W.; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9301202	A1	19930121	WO 1992-US5324	19920625	<--
	W: AU, BR, CA, FI, JP, KR, NO					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE					
	CA 2111571	A1	19930121	CA 1992-2111571	19920625	<--
	CA 2111571	C	20050823			
	CA 2504078	A1	19930121	CA 1992-2504078	19920625	<--
	CA 2504078	C	20070828			
	AU 9222544	A	19930211	AU 1992-22544	19920625	<--
	AU 667676	B2	19960404			
	EP 594667	A1	19940504	EP 1992-914215	19920625	<--
	EP 594667	B1	20010919			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE					
	JP 06508846	T	19941006	JP 1993-502244	19920625	<--
	JP 2584947	B2	19970226			
	AT 205850	T	20011015	AT 1992-914215	19920625	<--
	ES 2160579	T3	20011116	ES 1992-914215	19920625	<--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703	<--
	IL 102407	A	19970110	IL 1992-102407	19920703	<--
	CN 1071577	A	19930505	CN 1992-108868	19920704	<--
	CN 1050996	C	20000405			
	IN 175688	A1	19950812	IN 1992-CA473	19920706	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	HK 1003424	A1	20020215	HK 1998-102605	19980327	<--
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	GR 3036749	T3	20011231	GR 2001-401606	20010927	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
PRAI	US 1991-724340	A	19910705	<--		
	US 1992-903107		19920625	<--		
	CA 1992-2111571	A3	19920625	<--		
	WO 1992-US5324	A	19920625	<--		
	IN 1992-CA473	A1	19920706	<--		
	AU 1995-29150	A3	19950630			
	AU 1999-52624	A3	19991001			
	AU 2002-320811	A3	20021223			

OS MARPAT 118:205218
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of 5-fluorouridine via fluorination of triacetyluridine in acetic acid.
AB Title compound (I), a known neoplasm inhibitor, was prepared in high yield and purity by reaction of triacetyluridine with F in AcOH followed by (stepwise) deacetylation of the intermediate 6-acetoxy-triacetyl-5-fluoro-5,6-dihydrouridine (II). Thus, F in N was introduced over 24 h into a solution of 3.7 g triacetyluridine in 200 mL AcOH. The resulting II which was dissolved in 80 mL 0.15 M NaOMe in MeOH and allowed to stand for 12 h at ambient temperature to give 2.15 g

(82%) I, m. 183-185°. I was prepared in 71% overall yield by 2-step deacetylation of II using Et3N to dehydroacetylate the 6-acetoxy group followed by deacetylation of the resulting triacetyl-5-fluorouridine by the Zemplen technique.

AN 1991:559681 HCAPLUS <<LOGINID::20100301>>
DN 115:159681
OREF 115:27363a,27366a
TI Preparation of 5-fluorouridine via fluorination of triacetyluridine in acetic acid.
IN Beranek, Jiri; Hrebabecky, Hubert; Brokes, Josef; Novotny, Ladislav
PA Czech.
SO Czech., 2 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 264903	B1	19890912	CS 1984-1315	19840224 <--
PRAI CS 1984-1315		19840224 <--		

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 8 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of carcinostatic nucleosides of 6-acetoxy-5-fluoro-5,6-dihydrouracil
GI



I

AB The title compds. (I; R = 2,3,5-tri-O-acetylribosyl, 2,3-di-O-acetyl-5-deoxyribosyl, 2,3-di-O-acetyl-5-chloro-5-deoxyribosyl) were prepared as new carcinostatics (no data), by a direct fluorination of acetyluracil nucleosides with F(g) in AcOH. Thus, F(g) was introduced over 24 h into a solution of 3.7 g triacetyluridine in 200 mL AcOH, to give 4.22 g title compound I (R = 2,3,5-tri-O-acetylribosyl). Deacetylation of the latter by MeONa in MeOH gave 2.39 g 5-fluorouridine.

AN 1991:515021 HCAPLUS <<LOGINID::20100301>>
DN 115:115021
OREF 115:19745a,19748a
TI Preparation of carcinostatic nucleosides of 6-acetoxy-5-fluoro-5,6-dihydrouracil
IN Beranek, Jiri; Hrebabecky, Hubert; Brokes, Josef; Novotny, Ladislav
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT Patent
LA Czech
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI CS 264904	B1	19890912	CS 1984-1316	19840224 <--
PRAI CS 1984-1316		19840224 <--		

OS MARPAT 115:115021

L3 ANSWER 9 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Crystal and molecular structure of
4-(1,2,4-triazol-1-yl)-2',3',5'-tri-O-acetyluridine, C17H19N5O8
AB The title compound is orthorhombic, space group P212121, with a 5.764(2), b
10.587(2), and c 33.778(6) Å; dc = 1.358 for Z = 4. The final R =
0.039 and Rw = 0.032 for 1174 reflections. Atomic coordinates are given.
Bond lengths and bond angles are given, and the sugar conformation
discussed.
AN 1989:31691 HCAPLUS <<LOGINID::20100301>>
DN 110:31691
OREF 110:5189a,5192a
TI Crystal and molecular structure of
4-(1,2,4-triazol-1-yl)-2',3',5'-tri-O-acetyluridine, C17H19N5O8
AU Smykalla, Cornelia; Smits, J. M. M.; Beurskens, Gezina; Beurskens, Paul
T.; Rijk, E. A. V.; Tesser, G. I.
CS Crystallogr. Lab., Univ. Nijmegen, Nijmegen, 6525 ED, Neth.
SO Journal of Crystallographic and Spectroscopic Research (1988),
18(4), 457-63
CODEN: JCREDB; ISSN: 0277-8068
DT Journal
LA English

L3 ANSWER 10 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of 5-(perfluoroalkyl)uridine derivatives as intermediates for
antiviral agents
GI



I

AB The title derivs. I (R1 = H, OAc; R2 = lower perfluoroalkyl) (II), useful
as intermediates for antiviral agents, are prepared from I (R2 = H) (III)
with R2CO2H (R2 = same as II) in the presence of XeF2. XeF2 was gradually
added to a solution of III (R1 = OAc), CF3CO2H, in CH2Cl2 at room temperature
and
the reaction mixture was further stirred for 5 h to give 88% II (R1 = OAc,
R2 = CF3) (IV). IV was dissolved in NH3-saturated MeOH and the solution was
left
stand overnight, concentrated, and then treated with hexane/ether in a
refrigerator to give 71% 5-(trifluoromethyl)uridine.
AN 1989:24249 HCAPLUS <<LOGINID::20100301>>
DN 110:24249

OREF 110:4113a,4116a
TI Preparation of 5-(perfluoroalkyl)uridine derivatives as intermediates for antiviral agents
IN Tanabe, Akira; Matsuo, Noritada
PA Sumitomo Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 63188696	A	19880804	JP 1987-19128	19870129 <--
PRAI JP 1987-19128		19870129 <--		

OS MARPAT 110:24249

L3 ANSWER 11 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Oxidation of pyrimidine base derivatives with m-chloroperbenzoic acid
AB Oxidns. of 1,3-dimethylthymine (I), 3',5'-diacetylthymidine (II), 1,3-dimethyluracil (III), 5-fluoro-1,3-dimethyluracil (IV), and 2',3',5'-triacetyluridine with m-chloroperbenzoic acid were studied. A plausible mechanism for formation of the oxidation products was given.
AN 1987:137752 HCAPLUS <<LOGINID::20100301>>
DN 106:137752
OREF 106:22461a,22464a
TI Oxidation of pyrimidine base derivatives with m-chloroperbenzoic acid
AU Harayama, Takashi; Kotoji, Kayoko; Yanada, Reiko; Yoneda, Fumio; Taga, Tooru; Osaki, Kenji; Nagamatsu, Tomohisa
CS Fac. Pharm. Sci., Kyoto Univ., Kyoto, 606, Japan
SO Chemical & Pharmaceutical Bulletin (1986), 34(6), 2354-61
CODEN: CPBTAL; ISSN: 0009-2363
DT Journal
LA English
OS CASREACT 106:137752

L3 ANSWER 12 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Synthesis of covalently-linked double-helical cross sections representative of purine-purine and pyrimidine-pyrimidine duplexes
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Covalently-linked double-helical cross sections I and II (R = OH, H) that resemble A-I base pairing and hypothetical C-U(T) base pairing resp., have been prepared in short reaction sequences from acetylated ribo- or deoxyribonucleosides. I represent a covalently linked purine-purine long base-pair mimic of a bulge in a double-helical RNA or DNA cross-section. II represent a covalently linked pyrimidine-pyrimidine short base-pair, analogous to a pinched-in RNA or DNA cross-section. I (R = OH) was prepared by reaction of tri-O-acetyladenosine with ClCH:C(OEt)2 to give the chloroimidate, condensation of the latter with tri-O-acetyladenosine in the presence of an acid catalyst to yield amine III, oxidative ring closure of III with 2-O2NC6H4I(OAc)2 in (CF3)2CMeOH-MeNO2, and deacetylation by NH3-MeOH .
AN 1987:67619 HCAPLUS <<LOGINID::20100301>>
DN 106:67619
OREF 106:11139a,11142a
TI Synthesis of covalently-linked double-helical cross sections

representative of purine-purine and pyrimidine-pyrimidine duplexes
AU Leonard, Nelson J.; Devadas, Balekudru
CS Sch. Chem. Sci., Univ. Illinois, Urbana, IL, 61801-3731, USA
SO Journal of the American Chemical Society (1987), 109(2), 623-5
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA English
OS CASREACT 106:67619

L3 ANSWER 13 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Reaction of uracil derivatives with difluorocarbene
GI



I II III

AB Uridines I (R = H, Me; R1 = H, OH; R2 = CF2H; R3 = H) were prepared by silylation of triacetyluridine and diacetylthymidine with NH(SiMe3)2. I (R1 = H, OAc; R2 = SiMe3; R3 = Ac) were desilylated with Hg(CF3)2 to produce I (R1 = H, OAc; R2 = CF2H; R3 = Ac) and subsequent hydrolysis produced I (R1 = H, OH; R2 = CF2H; R3 = H). The silylation and difluorocarbene insertion reactions were also completed on the nucleoside bases to yield the bis(fluoromethyl) and difluoromethyl adducts II and III.
AN 1986:424561 HCAPLUS <<LOGINID::20100301>>
DN 105:24561
OREF 105:4141a,4144a
TI Reaction of uracil derivatives with difluorocarbene
AU Pein, Claus Dietmar; Cech, Dieter
CS Sekt. Chem., Humboldt-Univ. Berlin, Berlin, DDR-1040, Ger. Dem. Rep.
SO Zeitschrift fuer Chemie (1985), 25(9), 328-9
CODEN: ZECEAL; ISSN: 0044-2402
DT Journal
LA German
OS CASREACT 105:24561
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 14 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation of 3'-O-(4-methoxytetrahydropyran-4-yl) derivatives of 4-N-benzoylcytidine and uridine
GI



AB The title compds. I and III were prepared from N4,2'-O,5'-O-triacetylcytidine in 54 and 65% overall yields, resp. 3'-O-(4-Methoxytetrahydropyran-4-yl)cytidine (III) was the common intermediate for both I and II.
AN 1986:110097 HCAPLUS <<LOGINID::20100301>>
DN 104:110097
OREF 104:17469a
TI Preparation of 3'-O-(4-methoxytetrahydropyran-4-yl) derivatives of 4-N-benzoylcytidine and uridine
AU Norman, David G.; Reese, Colin B.
CS Dep. Chem., King's Coll., London, WC2R 2LS, UK
SO Synthesis (1985), (9), 874-5
CODEN: SYNTBF; ISSN: 0039-7881
DT Journal
LA English
OS CASREACT 104:110097
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 15 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Synthesis of C-5 and N-3 arenesulfenyl uridines. Preparation and properties of a new class of uracil protecting group
GI



AB The nature and position of the ring substituent of an arenesulfenyl chloride control the regiospecific formation of either a C-5 substituted product, as in (arenesulfenyl)uridines I (R = Ph, p-MeC6H4, p-ClC6H4, p-O2NC6H4), or a N-3 substituted product, as in II [R = 2-O2NC6H4, 4,2-Me(O2N)C6H3, 2,4-(O2N)2C6H3]. Arenesulfenyl groups successfully protect the urethane function of the uracil residue as exemplified by the synthesis of 2'-O-methyluridine and oligoribonucleotide building blocks.
AN 1985:578555 HCAPLUS <<LOGINID::20100301>>
DN 103:178555
OREF 103:28751a,28754a
TI Synthesis of C-5 and N-3 arenesulfenyl uridines. Preparation and properties of a new class of uracil protecting group
AU Welch, C. J.; Bazin, H.; Heikkila, J.; Chattopadhyaya, J.
CS Biomed. Cent., Uppsala Univ., Uppsala, S-751 23, Swed.
SO Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1985), B39(3), 203-12
CODEN: ACBOCV; ISSN: 0302-4369
DT Journal
LA English
OS CASREACT 103:178555
OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L3 ANSWER 16 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Studies on oxidative modifications of nucleic acid pyrimidine bases
GI



I

AB Oxidation of diacetylthymidine, triacetyluridine, and 5-fluoro-1,3-dimethyluracil with m-chloroperbenzoic acid occurred at the double bond in the pyrimidine base. Cross-linkage of the bromohydrin I (R = β-Br, R1 = α-OH) with PhCH2NH2 and glycine Et ester gave I (R = OH, R1 = NHCH2Ph, NHCH2CO2Et). A mechanism for the formation of oxidation products is presented.
AN 1985:505252 HCAPLUS <<LOGINID::20100301>>
DN 103:105252
OREF 103:16873a,16876a
TI Studies on oxidative modifications of nucleic acid pyrimidine bases
AU Harayama, Takashi; Yanada, Reiko; Kotoji, Kayoko; Yoneda, Fumio; Taga, Toru; Osaki, Kenji; Nagamatsu, Tomohisa
CS Fac. Pharm. Sci., Kyoto Univ., Kyoto, 606, Japan
SO Nucleic Acids Symposium Series (1984), 15(Symp. Nucleic Acids Chem.), 1-4
CODEN: NACSD8; ISSN: 0261-3166
DT Journal
LA English
OS CASREACT 103:105252

L3 ANSWER 17 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Triazenes as transport form of sulfur mustard: synthesis of 3-[S-(2-chloroethyl)thioethyl]aryltriazenes and study of their reactions

in aqueous and nonaqueous solutions
AB A group of biol. active 1-aryl-3-[S-(2-chloroethyl)thioethyl]triazenes has been synthesized. The rates of decomposition of 4-NCC6H4NHN:NCH2CH2SCH2CH2Cl (I), determined polarog., increase with decrease in pH from 7.1 to 5.1. A deuterated triazene discriminated between alternative decomposition pathways. The data are consistent with initial protonation of the triazene and generation of a S-(2-chloroethyl)thioethyl cation (or its kinetic equivalent) which undergoes rearrangements as detected by deuterium scrambling. A second competing pathway may involve cyclization of the triazene to a 1-aryl-1,2,3-triazathiaoctene intermediate which then undergoes nucleophilic opening with loss of N. These triazenes readily esterify 3,5-(O2N)2C6H3CO2H and (EtO)2P(O)OH in Et2O solns. The use of the D labeled triazene indicates that these triazenes esterify predominantly via ion-pair mechanism and SN2 displacement is the minor pathway. I alkylated the N3-position of triacetyluridine, also via a combination of ion-pair and SN2 displacement mechanisms as determined D labeling. These studies are expected to assist in the interpretation of the cytotoxic effects of these triazenes.
AN 1985:131602 HCAPLUS <<LOGINID::20100301>>
DN 102:131602
OREF 102:20643a,20646a
TI Triazenes as transport form of sulfur mustard: synthesis of 3-[S-(2-chloroethyl)thioethyl]aryltriazenes and study of their reactions in aqueous and nonaqueous solutions
AU Singh, Ranjit
CS Dep. Chem., Univ. Alberta, Edmonton, AB, T6G 2G2, Can.
SO Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1984), 23B(11), 1088-97
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English

L3 ANSWER 18 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Structural assignment of N3-acylated uridine derivatives by means of carbon-13 NMR spectroscopy
AB (Me2CH)2NEt was effective as a base for acylation of 2',3',5'-tri-O-acetyluridine with various acid chlorides. The 13C NMR spectra of the products and related compds. showed clearly that the acyl group introduced into the uracil moiety was attached at N-3.
AN 1985:24979 HCAPLUS <<LOGINID::20100301>>
DN 102:24979
OREF 102:4135a,4138a
TI Structural assignment of N3-acylated uridine derivatives by means of carbon-13 NMR spectroscopy
AU Kamimura, Takashi; Masegi, Tsukio; Sekine, Mitsuo; Hata, Tsujiaki
CS Dep. Life Chem., Tokyo Inst. Technol., Yokohama, 227, Japan
SO Tetrahedron Letters (1984), 25(38), 4241-4
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L3 ANSWER 19 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Hydrogen bond equilibrium constants of some unusual nucleotide base pairs
GI



I



II



III



IV

AB Approx. H bond association consts. were determined for base pairs formed by an adenine derivative (I) and a number of unusual pyrimidine bases [including ftorafur (II) and tri-O-acetyluridine (III)]. A series is found in which the H bond strength in the base pairs varies. In certain cases the H bond equilibrium constant is larger than in the adenine-thymine pair. Inosine derivs.
(IV) seem to have a nonnegligible chance of replacing guanosine in the guanosine-cytosine pair. IR, near-IR (overtone), and NMR spectra were used to determine the equilibrium consts.

AN 1984:586303 HCAPLUS <<LOGINID::20100301>>

DN 101:186303

OREF 101:28125a,28128a

TI Hydrogen bond equilibrium constants of some unusual nucleotide base pairs

AU Buchet, R.; Beauvais, Linda; Sandorfy, C.

CS Dep. Chim., Univ. Montreal, Montreal, QC, H3C 3V1, Can.

SO Journal of Biomolecular Structure & Dynamics (1984), 2(1), 221-32
CODEN: JBSDD6; ISSN: 0739-1102

DT Journal

LA English

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L3 ANSWER 20 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN

TI Structure of 2',3',5'-tri-O-acetyluridine, C15H18N2O9

GI



I

AB Crystal structure of the title compound (I) was determined The sugar-ring pucker
is 3T4 [C(3')-endo/C(4')-exo], with P = 46.5(6)°, and χCN
[C(2)-N(1)-C(1')-O(4')] is 74.2(6)°, in the syn range. A close
contact of 2·90(3) Å between acetyl oxygen and a neighboring
base ring is noted. The pyrimidine base ring is essentially planar, as
are the acetyl groups.
AN 1984:511332 HCAPLUS <<LOGINID::20100301>>
DN 101:111332
OREF 101:17017a,17020a
TI Structure of 2',3',5'-tri-O-acetyluridine, C15H18N2O9
AU Low, J. N.; Wilson, C. C.
CS Carnegie Lab. Phys., Univ. Dundee, Dundee, DD1 4HN, UK
SO Acta Crystallographica, Section C: Crystal Structure Communications (
1984), C40(6), 1030-2
CODEN: ACSCEE; ISSN: 0108-2701
DT Journal
LA English
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L3 ANSWER 21 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI 4-Substituted pyrimidine nucleosides
GI



I

AB Pyrimidine nucleosides and their analogs I (R = optionally substituted
monosaccharide, aryl, alkyl, heterocyclic; R1 = optionally substituted
amino, N3, optionally substituted SH, halogen; R2 = halogen, optionally
substituted alkyl, aryl, alkoxy; X = O, S, NH) were prepared from I (R1 =
OH) via their sulfonates. Thus, triacetyluridine was tosylated
and the ester treated with NH3-MeOH to give 82% cytidine.
AN 1980:568560 HCAPLUS <<LOGINID::20100301>>

DN 93:168560
OREF 93:26863a,26866a
TI 4-Substituted pyrimidine nucleosides
IN Baerwolff, Dieter; Demirov, G. D.; Golovinskii, E. V.
PA Akademie der Wissenschaften der DDR, Zentralinstitut fuer Molekularbiologie, Ger. Dem. Rep.
SO Ger. (East), 7 pp.
CODEN: GEXXA8
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DD 140254	A1	19800220	DD 1978-209494	19781204 <--
PRAI DD 1978-209494	A1	19781204 <--		

L3 ANSWER 22 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Synthesis of dicytidylyl-(3'-5')-1,2-di(adenosin-N6-yl)ethane and dicytidylyl-(3'-5')-1,4-di(adenosin-N6-yl)butane: covalently joined terminals of two transfer ribonucleic acids and their behavior toward snake venom phosphodiesterase
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The chemical synthesis of the title bridged trinucleoside diphosphates, I and II, along with the corresponding dinucleoside phosphates, III and IV is described. Bridged nucleosides, V and VI, gave on treatment with tri-Et orthoformate in the presence of p-toluenesulfonic acid in DMF the cyclic orthoesters, VII and VIII. Condensation of VII and VIII with N,2',5'-O-triacetylcytidine 3'-phosphate, using dicyclohexylcarbodiimide in pyridine, afforded after deblocking and chromatog. separation, products I-IV. The latter were readily degraded with pancreatic RNase, but I and III were completely resistant toward snake venom phosphodiesterase, whereas II and IV were digested to the extent of 65 and 43%, resp. The major product of degradation of II with phosphodiesterase was IV, resulting from the combined action of phosphodiesterase and contaminating phosphomonoesterase. The results are explained in terms of stacking of terminal bridged nucleoside units in I-IV. The implications of these findings for the function of snake venom phosphodiesterase are discussed.
AN 1980:54061 HCAPLUS <<LOGINID::20100301>>
DN 92:54061
OREF 92:8927a,8930a
TI Synthesis of dicytidylyl-(3'-5')-1,2-di(adenosin-N6-yl)ethane and dicytidylyl-(3'-5')-1,4-di(adenosin-N6-yl)butane: covalently joined terminals of two transfer ribonucleic acids and their behavior toward snake venom phosphodiesterase
AU Zemlicka, Jiri
CS Sch. Med., Wayne State Univ., Detroit, MI, 48201, USA
SO Biochemistry (1980), 19(1), 163-8
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L3 ANSWER 23 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Cytidylyl-(3'- → 5')-3'-N-mercaptoacetylpuromycin aminonucleoside synthesis and its reaction with [3H]-N-acetyl-L-phenylalanyl-tRNA on E.

coli and rat liver ribosomes
AB A thiol-containing dinucleoside derivative of puromycin, cytidylyl-(3'→5')-3'-N-mercaptoacetylpyromycin amino nucleoside (I), was synthesized and its ability to release N-acetyl-L-phenylalanine from tRNA on Escherichia coli and rat liver ribosomes was evaluated. I was as active as puromycin in reacting with 3H-labeled N-acetyl-L-phenylalanyl-tRNA on E. coli ribosomes but only moderately active in the rat liver system. Chromatog. anal. of assay products revealed covalent attachment of N-acetyl-L-phenylalanine-3H to the dinucleoside derivative Results obtained here show that an inactive thiopuromycin derivative [3']-N-mercaptoacetylpuromycin aminonucleoside becomes a potent acceptor of N-acetyl-L-phenylalanine from E. coli ribosomes when substituted in the 5'-position by a cytidine-3'-phosphate residue.
AN 1979:134106 HCAPLUS <<LOGINID::20100301>>
DN 90:134106
OREF 90:21183a,21186a
TI Cytidylyl-(3'- → 5')-3'-N-mercaptoacetylpuromycin aminonucleoside synthesis and its reaction with [3H]-N-acetyl-L-phenylalanyl-tRNA on E. coli and rat liver ribosomes
AU Ariatti, Mario; Hawtrey, Arthur O.
CS Dep. Biochem., Univ. Rhodesia, Salisbury, Rhodesia
SO South African Journal of Science (1978), 74(11), 432-5
CODEN: SAJSAR; ISSN: 0038-2353
DT Journal
LA English

L3 ANSWER 24 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI 5-Fluorouridine and 5-fluorocytidine. Direct fluorination of the pyrimidine ring
AB 5-Fluorouridine was prepared by treatment of 2',3',5'-tri-O-acetyluridine with CF3OF-CCl3F in CHCl3 at -78° followed by deacetylation. 5-Fluorocytidine HCl was prepared similarly from N4-acetyl-2',3',5'-tri-O-acetylcytidine.
AN 1979:6656 HCAPLUS <<LOGINID::20100301>>
DN 90:6656
OREF 90:1221a,1224a
TI 5-Fluorouridine and 5-fluorocytidine. Direct fluorination of the pyrimidine ring
AU Robins, Morris J.; MacCoss, Malcolm; Naik, S. R.
CS Dep. Chem., Univ. Alberta, Edmonton, AB, Can.
SO Nucleic Acid Chem. (1978), Volume 2, 895-900. Editor(s): Townsend, Leroy B.; Tipson, R. Stuart. Publisher: Wiley, New York, N. Y.
CODEN: 39GCA6
DT Conference
LA English

L3 ANSWER 25 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Olefin cycloadditions to 2',3',5'-triacetyluridine
AB Photocycloaddn. of 2',3',5'-tri-O-acetyluridine occurred quant. with tetramethylethylene, isopropenyl acetate, (EtO)2C:CH2 and vinylene carbonate (I). The adduct with I on solution in EtOH-Et3N gave 5-carboxymethyl-2',3',5'-tri-O-acetyluridine.
AN 1976:543386 HCAPLUS <<LOGINID::20100301>>
DN 85:143386
OREF 85:22993a,22996a
TI Olefin cycloadditions to 2',3',5'-triacetyluridine
AU Charlton, James L.; Lai, Hoi Kiong
CS Dep. Chem., Univ. Manitoba, Winnipeg, MB, Can.
SO Canadian Journal of Chemistry (1976), 54(9), 1445-8
CODEN: CJCHAG; ISSN: 0008-4042

DT Journal
LA English
OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L3 ANSWER 26 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI 5-Mercaptopyrimidine nucleosides through one-step synthesis of 5-thiocyanatouridine and -2'-deoxyuridine
GI For diagram(s), see printed CA Issue.
AB Uridine with NCSCl in AcOH for 1 hr gave 48% 5-thiocyanatouridine (I). Similarly 2 -deoxyuridine and 2 ,3 ,5 -triacetyluridine gave 55% and 96%, resp., of the corresponding 5-thiocyanato derivs. Reduction of I with Na dithionite-mercaptoethanol or dithiothreitol gave 5-mercaptouridine.
AN 1972:552489 HCAPLUS <<LOGINID::20100301>>
DN 77:152489
OREF 77:25083a,25086a
TI 5-Mercaptopyrimidine nucleosides through one-step synthesis of 5-thiocyanatouridine and -2'-deoxyuridine
AU Nagamachi, T.; Torrence, P. F.; Waters, J. A.; Witkop, B.
CS Lab. Chem., Natl. Inst. Health, Bethesda, MD, USA
SO Journal of the Chemical Society, Chemical Communications (1972), (18), 1025-6
CODEN: JCCCAT; ISSN: 0022-4936
DT Journal
LA English

L3 ANSWER 27 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Nucleic acid components and their analogs. CXLVII. Preparation of 5-ethoxycarbonyluridine, 5-carboxyuridine, and their nucleotidic derivatives
AB A mixture of EtO2CCH2COCl and H2NCO2Et stirred at 100° gave EtO2CCH2CONHCO2Et, which refluxed with Ac2O and HC(OEt)3 gave (E)-EtO-CH:C(CO2Et)CONHCO2Et. Condensation of the latter compound with 2,3-O-isopropylidene-β-D-ribofuranosylamine p-toluenesulfonate and removal of the :CMe2 group gave 5-ethoxycar-bonyluridine (I), which was hydrolyzed to give 5-carboxyuridine (II). I or II treated successively with P(OEt)3 and (C13C)2CO gave the 2',3'-cyclic phosphates of I and II resp. (substrates for pancreatic ribonuclease and ribonuclease T2). Treatment of II with POCl3 in OP(OEt)3 gave II 5'-phosphate, which was dephosphorylated by the snake venom 5'-nucleotidase. Uridylyl-(3' → 5')-5- ethoxycarbonyluridine and guanylyl-(3' → 5')-5-ethoxycarbonyluridine were split by the snake venom phosphodiesterase while uridylyl-(3' → 5')-5-carboxyuridine and guanylyl-(3' → 5')-5-carboxyuridine were resistant in this respect.
AN 1972:502109 HCAPLUS <<LOGINID::20100301>>
DN 77:102109
OREF 77:16843a,16846a
TI Nucleic acid components and their analogs. CXLVII. Preparation of 5-ethoxycarbonyluridine, 5-carboxyuridine, and their nucleotidic derivatives
AU Holy, Antonin
CS Cesk. Akad. Ved, Prague, Czech.
SO Collection of Czechoslovak Chemical Communications (1972), 37(5), 1555-76
CODEN: CCCCAK; ISSN: 0010-0765
DT Journal
LA English

L3 ANSWER 28 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Purine derivatives
AB Triacetyluridine (333 mg) and 684 mg theophylline are heated 10

hr at 170° with 381 mg BzCl, 410 mg SbCl3, 3 ml xylene, and 2 ml PhNO2 and cooled, 0.1N ethanolic NH4OH added, the mixture evaporated in vacuo, and the residue extracted with CHCl3 to give 276 mg 7-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)theophylline, amorph. Similarly prepared are 2',3',5'-tri-O-acetyl-N6-benzoyladenosine, 9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-6-dimethylaminopurine, 2',3',5'-tri-O-acetylinosine, 7-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-N'-acetylguanine, 9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-N'-acetylguanine, and 2',3'-di-O-benzoyl-5'-diphenylphosphoryl-β-D-ribofurano-syltheophylline.

AN 1971:142301 HCAPLUS <<LOGINID::20100301>>
DN 74:142301
OREF 74:23003a,23006a
TI Purine derivatives
IN Shimizu, Bunji; Miyagi, Michiko
PA Sankyo Co., Ltd.
SO Jpn. Tokkyo Koho, 7 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 46005710	B4	19710212	JP	19670810 <--

L3 ANSWER 29 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Oligonucleotidic compounds. XXXV. Reaction of diribonucleoside phosphates with dimethylformamide acetals
AB NH4 (Et3NH, BuMe3N) salts of some diribonucleoside phosphates (U pU, UpC, UpA, UpI, ApU, GpU, CpI, and CpX) containing uridine (I), inosine, or xanthosine were methylated with Me2NCH(OMe)2 (II) in HCONMe2 (or Me2SO) at 60° to the corresponding derivs. of N3-methyluridine (III), N1-methylinosine, and N-methylxanthosine (in the last case, the exact position of the Me group was not determined). The methylation was not accompanied by any isomerization of the 3' → 5' internucleotide linkage or any other side-reactions. After 3 (19) hr at 60°, II and UpU NH4 salt gave 27 (15) % uridylyl-(3' → 5')-N3-methyluridine (IV), 27 (18) % N3-methyluridylyl-(3' → 5')-uridine, 29 (60) % N3-methyluridylyl-(3' → 5')-N3-methyluridine, and 17 (7) % UpU. After 5 hr at 60°, II and UpI NH4 salt gave 7% uridylyl-(3' → 5')-N1-methylinosine, 33% N3-methyluridylyl-(3' → 5')-inosine, 43% N3-methyluridylyl-(3' → 5')-N1-methylinosine (V), and 17% UpI (after 18 hr, 100% V resulted). UpC NH4 salt and II (12 hr at 60°) gave 100% N3-methyluridylyl-(3' → 5')-cytidine. UpA NH4 salt and II (24 hr at 60°) gave 75% N3-methyluridylyl-(3' r 5')-adenosine. ApU and II (12 hr at 60°) gave 100% adenosine-(3' → 5')-N3-methyl uridine. GpU Et3NH salt (7 hr at 60°) gave 95% guanosine-(3' → 5')-N3-me thyluridine. The internucleotide linkage of some diribonucleoside phosphates (NH4 salts) derived from cytidine 3'-phosphate (CpU, CpA, and CpC) was cleaved by II at 60° or Me2NCH(OCH2CMe3)2 (VI) at 80° with the formation of cytidine 2',3'-cyclic phosphate (VII) and the corresponding nucleoside (or its N-Me derivative). Thus, the reaction of CpU NH4 salt and II (6 hr at 60°) gave 2.5% cytidylyl-(3' → 5')-N3-methyluridine, 73% VII, 21% cytidine 2'(3')-phosphate Me ester, 3.5% CpU, 25% I, and 75% III. CpG, ApC, 2'-deoxycytidylyl-(3' → 5')-adenosine, cytidylyl-(3' → 5')-8-bromoinosine (VIII), and cytidylyl-(3' → 5')-8-dimethylaminoinosine (IX) did not react with II or VI. CpU Bu3MeN salt and II (18 hr at 60°) gave 90% cytidylyl-(3' → 5')-N3-methyluridine. CpI, CpX, VIII, and IX were prepared by the

N,N'-dicyclohexyl-carbodiimide condensation of N4,O2',O5'-triacetylcytidine 3'-phosphate with 2',3'-O-ethoxymethyleneinosine, 2',3'-O-eth-oxymethylenexanthosine, 2',3'-O-ethoxymethylene-8-bromoinosine, and 2',3'-O-ethoxymethylene-8-dimethylaminoinosine, resp., deacetylation (with aqueous NH3), and removal of the ethoxymethylene group with aqueous AcOH. IV was prepared similarly from 2',5'-di-O-acetyluridine 3'-phosphate and 2',3'-O-ethoxymethylene-N3-methyluridine. The stability of the 3' → 5' internucleotide linkage in various diribonucleoside phosphates or their derivs. to II or VI is discussed.

AN 1970:44054 HCAPLUS <<LOGINID::20100301>>
DN 72:44054
OREF 72:8118h,8119a
TI Oligonucleotidic compounds. XXXV. Reaction of diribonucleoside phosphates with dimethylformamide acetals
AU Holy, Antonin; Zemlicka, Jiri
CS Cesk. Akad. Ved, Prague, Czech.
SO Collection of Czechoslovak Chemical Communications (1969), 34(12), 3921-35
CODEN: CCCCAK; ISSN: 0010-0765
DT Journal
LA English

L3 ANSWER 30 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Synthesis of oligoribonucleotides. VI. 2'-O-Acyl ribonucleoside derivatives as intermediates in the synthesis of dinucleoside phosphates
AB N2,O2',O5'-Tribenzoylguanosine (I) was obtained as a pure crystalline compound The di-ribonucleoside phosphate: guanylyl-(3' → 5')-uridine[GpU] and cytidylyl-(3' → 5')-uridine [CpU] were prepared in moderate yields by the condensation (in pyridine with mesitylenesulfonyl chloride as the condensing agent) between 2',3'-di-O-acetyluridine5'-phosphate and, I and N4,O2',O5'-triacetylcytidine, resp. The GpU was completely digested to guanosine 3'-phosphate and uridine in the presence of ribonuclease T1, while the CpU was .apprx.98% digested to cytidine 3'-phosphate and uridine in the presence of pancreatic ribonuclease. 22 references.
AN 1968:114909 HCAPLUS <<LOGINID::20100301>>
DN 68:114909
OREF 68:22179a,22182a
TI Synthesis of oligoribonucleotides. VI. 2'-O-Acyl ribonucleoside derivatives as intermediates in the synthesis of dinucleoside phosphates
AU Fromageot, H. P. M.; Reese, Colin B.; Sulston, J. E.
CS Univ. Chem. Lab., Cambridge, UK
SO Tetrahedron (1968), 24(9), 3533-40
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

L3 ANSWER 31 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Synthesis of oligo- and polynucleotides. VIII. Synthesis of dinucleotides from the ribose series with a terminal 3'-phosphate group
AB cf. CA 64: 14469b; 65: 10646g. Condensation of 0.1 millimole acylated ribomononucleotide (I) containing a free 3'-phosphate group and 0.3 millimole Et4N salt of a nucleoside 2',3'-cyclophosphate (II) with a free 5'-OH group in 1.5 ml. C5H5N and 0.5 g. dicyclohexylcarbodiimide for 3 days at room temperature and shaking in the dark, enzymic hydrolysis with ribonuclease at pH 7.0 for 3 hrs. at 37°, and removal of protecting groups with MeOH-NH3 during 0.5-12 hrs. gave the dinucleotide (III), which was purified on DEAE-cellulose. The following III were obtained in 20-40%

yields: adenyl-3(' → 5')-uridine 3'-phosphate, -cytidine 3'-phosphate and -guanosine 3'-phosphate; uridylyl-(3' → 5')-uridine 3'-phosphate, -cytidine 3'-phosphate and -guanosine 3'-phosphate; cytidylyl-(3' → 5')-uridine 3'-phosphate, -guanosine 3'-phosphate and -cytidine 3'-phosphate. N6,O2',O5'-Tribenzoyladenosine 3'-phosphate, 80-5% yield by conversion of 3'-adenylic acid to the Et4N salt (on an ion-exchange resin in the Et4N form), treatment with BzCl-C5H5N 1 hr. at room temperature, and precipitation of the I from C5H5N with Et2O.
Other I, prepared in the usual way, were N6-benzoyl-O2',O5'-diacetyladenosine 3'-phosphate, O2',O5'-diacetyluridine 3'-phosphate, and N6,O2',O5' - triacetylcytidine 3' - phosphate.
The cyclization method of Smrt and Sorm (CA 57: 3550i) was used to prepare II. N6-Benzoylcytidine 2',3'-cyclophosphate was prepared in 68.5% yield from reaction of 2 millimoles NH4 cytidine 2',3'-cyclophosphate and 20 millimoles N-benzoylimidazole in 200 ml. HCO-NMe2 for 5 days at room temperature, concentration at high vacuum, and precipitation of the product from C5H5N into
Et2O, then conversion as above into the Et4N salt.
AN 1967:491009 HCAPLUS <<LOGINID::20100301>>
DN 67:91009
OREF 67:17155a,17158a
TI Synthesis of oligo- and polynucleotides. VIII. Synthesis of dinucleotides from the ribose series with a terminal 3'-phosphate group
AU Rhaese, Hans J.; Siehr, Wolfgang; Cramer, Friedrich
CS Max-Planck-Inst. Exptl. Med., Goettingen, Fed. Rep. Ger.
SO Justus Liebigs Annalen der Chemie (1967), 703, 215-24
CODEN: JLACBF; ISSN: 0075-4617
DT Journal
LA German

L3 ANSWER 32 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. II. Synthesis of the 2'(3')-O-glycyl derivatives of uridylyl-(3' → 5')-uridyne, cytidylyl-(3' → 5')-adenosine, and uridylyl-(3' → 5')-adenosine using the corresponding D-ribonucleoside 2',3'-cyclic orthoesters
AB cf. CA 65: 15487d. The pyridinium salt of 2',5'-di-O-acetyluridine 3'-phosphate (Ia) (0.245 g.) and 0.46 g. uridine 2',3'-(cyclic orthoester) was repeatedly evaporated with pyridine, the residue kept with 2 g. N,N'-dicyclohexylcarbodiimide 3.5 days, and evaporated The product was kept 5 hrs. with NH3-saturated MeOH, evaporated, and chromatographed on DEAE-cellulose in
50% MeOH-0.2M NEt3 and on Whatman 3 MM paper to give 24.5% uridylyl-(3' → 5')-2',3'- o-(N-benzyloxycarbonylaminomethyl)ethoxymethyleneuridine (I) and uridin e2',3'-(cyclic phosphate) resulting as by-product. Hydrolysis of I in 20% AcOH 2.5 hrs. gave uridylyl-(3' → 5')-2'(3')-(N-benzyloxycarbonyl)glycyluridine, yielding on hydrogenolysis over Pd/BaSO4 in 80% AcOH 97% uridylyl-(3' → 5')-2'(3')-O-glycyluridine. Analogously obtained were 20.7% cytidylyl-(3' → 5')-2',3' - O - (N - benzyloxycarbonyl)aminomethylethoxymethyleneadenosine (II) from 0.134 g. N,2',5'-O-triacetylcytidine 3'-phosphate and 0.5 millimole N-dimethylaminomethylene-2',3'-O-(N-benzyloxycarbonyl)aminomethylethoxymethyleneadenosine (III) in addition to the by-product cytidine 2',3'-cyclic phosphate, and 17.5% 2'-O-(1-ethoxyethyl)cytidylyl-(3' → 5')-2',3'-O-(N-benzyloxycarbonyl)aminomethylethoxymethyleneadenosine (IV) from 0.5 millimole IIIand 0.28 millimole N,5'-O-diacetyl-2'-O-(1-ethoxyethyl)cytidine3'-phosphate. IV gave on hydrolysis with 80% HCO2H at 0° 64% cytidylyl-(3' →

5')-2'(3')-O-(N-benzyloxycarbonyl)glycyladenosine which yielded on hydrogenolysis 66% cytidylyl-(3' → 5')-2'(3')-O-glycyladenosine. Similarly as above, 0.12 g. Ia and 0.27 g. III afforded 24% uridylyl-(3' → 5')-2',(3')-O-(N-benzyloxycarbonyl)aminomethylethoxymethyleneadenosine which was hydrolyzed to uridylyl-(3' → 5')-2'(3')-(N-benzyloxycarbonyl)glycyladenosine and this, in turn, hydrogenated to uridylyl-(3' → 5')-2'(3')-O-glycyladenosine. All compds. were characterized by paper chromatog. and electrophoresis, degradation with pancreatic ribonuclease, and uv spectra.

AN 1967:411694 HCAPLUS <<LOGINID::20100301>>
DN 67:11694
OREF 67:2247a,2250a
TI Aminoacyl derivatives of nucleosides, nucleotides, and polynucleotides. II. Synthesis of the 2'(3')-O-glycyl derivatives of uridylyl-(3' → 5')-uridyne, cytidylyl-(3' → 5')-adenosine, and uridylyl-(3' → 5')-adenosine using the corresponding D-ribonucleoside 2',3'-cyclic orthoesters
AU Chladek, Stanislav; Zemlicka, Jiri
CS Ceskoslov. Akad. Ved, Prague, Czech.
SO Collection of Czechoslovak Chemical Communications (1967), 32(5), 1776-89
CODEN: CCCCAK; ISSN: 0010-0765
DT Journal
LA English

L3 ANSWER 33 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI N4,O3',O5'-Triacetyl-2,2'-anhydrocytidine, a postulated reactive intermediate in a convenient synthesis of 1-β-D-arabinofuranosylcytosine
GI For diagram(s), see printed CA Issue.
AB cf. CA 61, 10763h. The effect of N4-acylation in the case of formation and resultant properties of 2,2'-anhydrocytidine derivs. was investigated. An equilibrium mixture of N4,O3',O5'-triacetylcytidine (I, R = H) (II) and its N4,O2',O5'-isomer in 3:2 ratio was prepared in 64% yield by the orthoester exchange method. The mixture was treated with a slight excess of p-MeC6H4SO2Cl in anhydrous C5H5N and the concentrated solution taken up in an equal volume of CH2Cl2, extracted with H2O in 10 min., and the extract kept at 20° to give N4,O3',O5'-triacetyl-β-D-arabinofuranosylcytosine (III, R = Ac) (IV). IV treated 24 hrs. at 20° gave 90% III (R = H) (V), m. 212-16°, [α]20D 152°. The tribenzoyl derivative (VI) in 9:1 C5H5N-H2O at 20° gave crystalline 1-β-D-arbinofuranosyl-N4O3',O5'-tribenzoylcytosine (VII), m. 198-200°, with 75% conversion after 11 days without indication of an intermediate. If the reaction proceeds via an anhydronucleoside its formation must be the rate-determining step and be extremely susceptible to base-catalyzed hydrolysis. It appears that the MeSO2 ion undergoes displacement much less readily than the p-MeC6H4SO2 ion in this reaction. IV has led to a very convenient synthesis of V which has selective antiviral activity. Both IV and VII have the correct orientation for preparation of the 2'-protected derivative of 1-β-D-arahinofuranosylcytosine, required in the oligonucleotide synthesis of Griffin and R. (CA 62, 2818a).

AN 1966:482561 HCAPLUS <<LOGINID::20100301>>
DN 65:82561
OREF 65:15484f-h,15485a
TI N4,O3',O5'-Triacetyl-2,2'-anhydrocytidine, a postulated reactive intermediate in a convenient synthesis of 1-β-D-arabinofuranosylcytosine
AU Fromageot, H. P. N.; Reese, C. B.

CS Univ. Cambridge, UK
SO Tetrahedron Letters (1966), (29), 3499-505
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English

L3 ANSWER 34 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Antimetabolites of uridine with two structural alterations
AB cf. C.A. 46, 5136b; 47, 9976f. Nucleosides substituted in both the 3- and 5-positions were prepared and their biol. activity compared with that of the corresponding derivs. with a single structural alteration. In the case of Neurospora, the 3,5-disubstituted nucleosides are less effective as antimetabolites than are the monosubstituted compds. Uridine (7.0 g.) in 100 cc. Ac2O let stand overnight at room temperature, the solution concentrated during 2 days at 4 mm. and 20-5° to a sirup, the triacetyluridine (I) (yield 90%) (19 g.) in a min. of hot (CH2Cl)2 cooled to 0°, treated with 5.3 g. CH2N2 in Et2O, let stand overnight at room temperature, concentrated to dryness in vacuo at room temperature, 50 cc. absolute MeOH added, the solution taken to dryness in vacuo, the residue refluxed 10 min. in 5% HCl-MeOH, the solution concentrated to dryness in vacuo at room temperature, the residue in a min. of cold water passed through 5 g. Amberlite IRA-400, the effluent decolorized with C, lyophilized, and the residue dissolved in 1:1 MeOH-EtOAc and treated with Et2O until opalescent, yielded 9.8 g. 3-methyluridine (II), m. 122-3°; at times a form m. 108-10° was obtained. The 2 forms could not be interconverted. II (2.6 g.) in water treated with Br water at 5° to a permanent color, the solution aerated, lyophilized, and the product refluxed 2 hrs. with absolute EtOH, and concentrated to a sirup on the water bath gave 3.10 g. 3-methyl-5-bromouridine (III), m. 164-4.5°. II (750 mg.) in 45 cc. AcOH treated with 0.32 g. Cl in cold CCl4 at room temperature, the solution let stand overnight, the solvent removed, the residue in 44 cc. MeOH containing 0.44 g. HCl let stand 2-5 days, and the acid removed by repeated addition and evaporation of MeOH gave 300 mg. 3-methyl-5-chlorouridine, m. 158-9°. III (1 g.) in 30 cc. absolute EtOH charged with 8 cc. NH3 (Dry Ice-Me2CO bath) in a stainless-steel tube, the tube let come to room temperature, heated 6 days at 55°, the NH3 and EtOH evaporated in vacuo at room temperature, the product in a min. of water passed through 5 g. IRA-120, the column washed with 3 l. water, eluted with 500 cc. 4N NH4OH, the NH3 removed in vacuo, the solution lyophilized, and the product recrystd. from absolute EtOH gave 400 mg. 3-methyl-5-aminouridine, m. 166-7°.
AN 1954:56477 HCAPLUS <<LOGINID::20100301>>
DN 48:56477
OREF 48:9922c-g
TI Antimetabolites of uridine with two structural alterations
AU Visser, Donald W.; Barron, Gerald; Beltz, Richard
CS Univ. of S. California, Los Angeles
SO Journal of the American Chemical Society (1953), 75, 2017-19
CODEN: JACSAT; ISSN: 0002-7863
DT Journal
LA Unavailable

L3 ANSWER 35 OF 35 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Ring structure of uridine
AB The acetylation of 10 g. uridine (I) with 130 cc. Ac2O containing 0.25 g. fused NaOAc and the isolation of the product (C. A. 26, 5571) gave 15 g. triacetyluridine, C15H18O9N2, as a pale yellow, flaky, glass-like

solid. This was hydrogenated in EtOAc in the presence of PtO2 at 45 lb. per sq. in pressure to triacetyldihydrouridine, which was methylated as previously described for the methylation of adenosine (C. A. 26, 2433). The simultaneous hydrolysis and oxidation of methylated dihydrouridine by the addition of Br to a solution in 3% aqueous HBr gave a mixture of trimethylribonolactone and its Me ester. Hydrolysis with 4% HCl at 85° for 2.5 hrs. yielded trimethyl-γ-ribonolactone, b0.05 90-5°, which on oxidation with concentrated HNO3 gave crystalline inactive dimethoxysuccinic acid; Me ester, m. 68°. It follows that I is a ribofuranoside.

AN 1933:50703 HCAPLUS <<LOGINID::20100301>>
DN 27:50703
OREF 27:4528e-g
TI Ring structure of uridine
AU Levene, P. A.; Tipson, R. Stuart
SO Journal of Biological Chemistry (1933), 101, 529-34
CODEN: JBCHA3; ISSN: 0021-9258
DT Journal
LA Unavailable

=> d his

(FILE 'HOME' ENTERED AT 13:41:33 ON 01 MAR 2010)

FILE 'REGISTRY' ENTERED AT 13:41:40 ON 01 MAR 2010
EXP TRIACETYLURIDINE/CN
EXP TRIACETYL URIDINE/CN
EXP 2,3,5-TRIACETYL URIDINE/CN
EXP ETHOXCARBONYLURIDINE\
EXP ETHOXCARBONYLURIDINE/CN
EXP PERACETYLURIDINE/CN
EXP PERACETYL URIDINE/CN

FILE 'HCAPLUS' ENTERED AT 13:43:26 ON 01 MAR 2010
L1 56 S TRIACETYLURIDINE OR (TRIACETYL URIDINE) OR TRIACETYLCYTIDINE
L2 56 S TRIACETYLURIDINE OR (TRIACETYL URIDINE) OR TRIACETYLCYTIDINE
L3 35 S L2 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	117.23	118.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-29.75	-29.75

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:45:29 ON 01 MAR 2010
Connection closed by remote host

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

```
LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 14:38:55 ON 01 MAR 2010
FILE 'HCAPLUS' ENTERED AT 14:38:55 ON 01 MAR 2010
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   120.14     121.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -29.75     -29.75

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   123.05     124.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -29.75     -29.75

FILE 'REGISTRY' ENTERED AT 14:39:14 ON 01 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 FEB 2010  HIGHEST RN 1207513-60-7
DICTIONARY FILE UPDATES:  28 FEB 2010  HIGHEST RN 1207513-60-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s 4105-38-8/rn
L4            1 4105-38-8/RN

=> s 5040-18-6/rn
L5            1 5040-18-6/RN

=> d l4

L4   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   4105-38-8  REGISTRY
```

ED Entered STN: 16 Nov 1984
CN Uridine, 2',3',5'-triacetate (CA INDEX NAME)
OTHER NAMES:
CN 2',3',5'-Tri-O-acetyluridine
CN 2',3',5'-Triacetyluridine
CN PN 401
CN RG 2133
CN Tri-O-acetyl uridine
CN Uridine triacetate
FS STEREOSEARCH
DR 293738-13-3
MF C15 H18 N2 O9
CI COM
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, IMSRESEARCH, RTECS*, TOXCENTER, USPAT2, USPATFULL, USPATOLD
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

251 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
251 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN
RN 5040-18-6 REGISTRY
ED Entered STN: 16 Nov 1984
CN Cytidine, N-acetyl-, 2',3',5'-triacetate (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetamide, N-(1,2-dihydro-2-oxo-1-β-D-ribofuranosyl-4-pyrimidinyl)-, triacetate (ester) (8CI)
OTHER NAMES:
CN Cytidine tetraacetate
CN N-Acetylcytidine triacetate
CN N4,2',3',5'-Tetraacetylcytidine
FS STEREOSEARCH
MF C17 H21 N3 O9
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMINFORMRX, SPECINFO, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

52 REFERENCES IN FILE CA (1907 TO DATE)
52 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.69	129.43
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-29.75

FILE 'HCAPLUS' ENTERED AT 14:39:49 ON 01 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Mar 2010 VOL 152 ISS 10
FILE LAST UPDATED: 28 Feb 2010 (20100228/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l4/thu
           251 L4
       1218718 THU/RL
L6          52 L4/THU
                 (L4 (L) THU/RL)

=> s l4/thu or l5/thu
           251 L4
       1218718 THU/RL
            52 L4/THU
                 (L4 (L) THU/RL)
            52 L5
       1218718 THU/RL
             0 L5/THU
                 (L5 (L) THU/RL)
L7          52 L4/THU OR L5/THU

=> s l7 and (PY<1993 or AY<1993 or PRY<1993)
      14944658 PY<1993
       2636069 AY<1993
       2076698 PRY<1993
L8           9 L7 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> d 18 1-9 ti abs bib

L8   ANSWER 1 OF 9  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Treatment of chemotherapeutic agent and antiviral agent toxicity with
     acylated pyrimidine nucleosides
AB   Compds., compns., and methods are disclosed for treatment and prevention
     of toxicity due to chemotherapeutic agents and antiviral agents.
     Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides.
     These compds. are capable of attenuating damage to the hematopoietic
     system in animals receiving antiviral or antineoplastic chemotherapy.
AN   1999:670113  HCAPLUS <<LOGINID::20100301>>
DN   131:281604
TI   Treatment of chemotherapeutic agent and antiviral agent toxicity with
     acylated pyrimidine nucleosides
IN   Von Borstel, Reid; Bamat, Michael K.
PA   Pro-Neuron, Inc., USA
SO   U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   US 5968914           A     19991019    US 1995-472210         19950607 <--
     EP 712629            A1    19960522    EP 1995-203050         19881027 <--
     EP 712629            B1    20030618
         R:  AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
     JP 10001436          A     19980106    JP 1997-36734          19881027 <--
     JP 3474073           B2    20031208
     JP 2001192335        A     20010717    JP 2000-379524         19881027 <--
     CA 2111571           A1    19930121    CA 1992-2111571        19920625 <--
     CA 2111571           C     20050823
     CA 2504078           A1    19930121    CA 1992-2504078        19920625 <--
     CA 2504078           C     20070828
     ES 2160579           T3    20011116    ES 1992-914215         19920625 <--
     ZA 9204975           A     19930428    ZA 1992-4975           19920703 <--
     IN 175688            A1    19950812    IN 1992-CA473          19920706 <--
     US 5246708           A     19930921    US 1992-911379         19920713 <--
```

	US 5470838	A	19951128	US 1992-997657	19921230	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	US 6020320	A	20000201	US 1993-153163	19931117	<--
	US 5736531	A	19980407	US 1993-176485	19931230	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	US 5770582	A	19980623	US 1995-419767	19950410	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6054441	A	20000425	US 1995-463790	19950605	<--
	US 6060459	A	20000509	US 1995-465016	19950605	<--
	US 7307166	B1	20071211	US 1995-463771	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	US 6348451	B1	20020219	US 1995-478736	19950607	<--
	US 6919320	B1	20050719	US 1995-473331	19950607	<--
	CA 2223640	A1	19961219	CA 1996-2223640	19960606	
	WO 9640165	A1	19961219	WO 1996-US10067	19960606	
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN					
	AU 9661114	A	19961230	AU 1996-61114	19960606	
	AU 724805	B2	20000928			
	EP 831849	A1	19980401	EP 1996-918461	19960606	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI					
	CN 1192149	A	19980902	CN 1996-195929	19960606	
	JP 10511689	T	19981110	JP 1997-502184	19960606	
	JP 2003201240	A	20030718	JP 2003-721	19960606	
	EP 1491201	A1	20041229	EP 2004-23557	19960606	
	EP 1491201	B1	20060322			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL					
	AT 320813	T	20060415	AT 2004-23557	19960606	
	ES 2257721	T3	20060801	ES 2004-23557	19960606	
	PT 1491201	E	20060831	PT 2004-23557	19960606	
	HK 1072897	A1	20060512	HK 2005-105421	19981003	
	US 20010025032	A1	20010927	US 1999-249790	19990216	<--
	US 6344447	B2	20020205			
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 6743782	B1	20040601	US 2000-494242	20000131	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040192635	A1	20040930	US 2004-824501	20040415	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
	JP 2009167213	A	20090730	JP 2009-110077	20090428	
PRAI	US 1987-115923	B2	19871028	<--		
	US 1987-115929	B2	19871028	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-487984	B2	19900205	<--		
	US 1991-724340	B2	19910705	<--		
	US 1992-903107	B2	19920625	<--		
	US 1993-61381	B2	19930514			
	US 1993-176485	A2	19931230			
	US 1988-186031	B2	19880425	<--		

```
     EP 1988-910239       A3    19881027  <--
     JP 1988-509176       A3    19881027  <--
     JP 1994-303877       A3    19881027  <--
     JP 2000-379524       A3    19881027  <--
     US 1989-341925       B1    19890421  <--
     US 1990-533933       B1    19900605  <--
     US 1990-438493       B2    19900626  <--
     US 1991-653882       B2    19910208  <--
     US 1991-737913       B3    19910729  <--
     CA 1992-2111571      A3    19920625  <--
     IN 1992-CA473        A1    19920706  <--
     US 1992-911379       A3    19920713  <--
     US 1992-925931       B2    19920807  <--
     US 1992-958598       B3    19921007  <--
     US 1992-987730       B2    19921208  <--
     US 1992-997657       A3    19921230  <--
     US 1993-96407        B1    19930726
     US 1993-98884        B1    19930729
     US 1993-153163       A1    19931117
     US 1993-158799       B2    19931201
     US 1994-266897       B3    19940701
     US 1994-289214       A3    19940812
     US 1995-419767       A3    19950410
     US 1995-463740       A1    19950605
     US 1995-472210       A     19950607
     AU 1995-29150        A3    19950630
     EP 1996-918461       A3    19960606
     JP 1997-502184       A3    19960606
     JP 2003-721          A3    19960606
     WO 1996-US10067      W     19960606
     HK 1998-111095       A3    19981003
     AU 1999-52624        A3    19991001
     US 2000-494242       A3    20000131
     AU 2002-320811       A3    20021223
     JP 2005-380457       A3    20051228
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   19    THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
RE.CNT  30    THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 2 OF 9  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Compositions of chemotherapeutic agent or antiviral agent with acylated
     pyrimidine nucleosides
AB   The subject invention discloses compds., compns. and methods for treatment
     and prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Thus, biol activity of 5-fluorouracil is reported.
AN   1998:236253  HCAPLUS <<LOGINID::20100301>>
DN   128:266247
OREF 128:52559a,52562a
TI   Compositions of chemotherapeutic agent or antiviral agent with acylated
     pyrimidine nucleosides
IN   Von Borstel, Reid W.; Bamat, Michael K.
PA   Pro-Neuron, Inc., USA
SO   U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 13
```

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5736531	A	19980407	US 1993-176485	19931230	<--
	EP 712629	A1	19960522	EP 1995-203050	19881027	<--
	EP 712629	B1	20030618			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	JP 10001436	A	19980106	JP 1997-36734	19881027	<--
	JP 3474073	B2	20031208			
	JP 2001192335	A	20010717	JP 2000-379524	19881027	<--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625	<--
	CA 2111571	C	20050823			
	CA 2504078	A1	19930121	CA 1992-2504078	19920625	<--
	CA 2504078	C	20070828			
	ES 2160579	T3	20011116	ES 1992-914215	19920625	<--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703	<--
	IN 175688	A1	19950812	IN 1992-CA473	19920706	<--
	US 5246708	A	19930921	US 1992-911379	19920713	<--
	US 5470838	A	19951128	US 1992-997657	19921230	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	US 6020320	A	20000201	US 1993-153163	19931117	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	US 5770582	A	19980623	US 1995-419767	19950410	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6054441	A	20000425	US 1995-463790	19950605	<--
	US 6060459	A	20000509	US 1995-465016	19950605	<--
	US 7307166	B1	20071211	US 1995-463771	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 5968914	A	19991019	US 1995-472210	19950607	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	US 6348451	B1	20020219	US 1995-478736	19950607	<--
	US 6919320	B1	20050719	US 1995-473331	19950607	<--
	US 7166581	B1	20070123	US 1995-473330	19950607	<--
	US 20010025032	A1	20010927	US 1999-249790	19990216	<--
	US 6344447	B2	20020205			
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 6743782	B1	20040601	US 2000-494242	20000131	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040192635	A1	20040930	US 2004-824501	20040415	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115923	B2	19871028	<--		
	US 1987-115929	B2	19871028	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-487984	B2	19900205	<--		
	US 1991-724340	B2	19910705	<--		
	US 1992-903107	B2	19920625	<--		
	US 1993-61381	B2	19930514			
	US 1988-186031	B2	19880425	<--		
	EP 1988-910239	A3	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	US 1989-341925	B1	19890421	<--		
	US 1990-533933	B1	19900605	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-653882	B2	19910208	<--		

US	1991-737913	B3	19910729	<--
CA	1992-2111571	A3	19920625	<--
IN	1992-CA473	A1	19920706	<--
US	1992-911379	A3	19920713	<--
US	1992-925931	B2	19920807	<--
US	1992-958598	B3	19921007	<--
US	1992-987730	B2	19921208	<--
US	1992-997657	A3	19921230	<--
US	1993-96407	B1	19930726	
US	1993-98884	B1	19930729	
US	1993-153163	A1	19931117	
US	1993-158799	B2	19931201	
US	1993-176485	A2	19931230	
US	1994-266897	B3	19940701	
US	1994-289214	A3	19940812	
US	1995-419767	A3	19950410	
US	1995-463740	A1	19950605	
US	1995-472210	A1	19950607	
AU	1995-29150	A3	19950630	
AU	1999-52624	A3	19991001	
US	2000-494242	A3	20000131	
AU	2002-320811	A3	20021223	
JP	2005-380457	A3	20051228	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 128:266247
OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.
AN 1997:141015 HCAPLUS <<LOGINID::20100301>>
DN 126:139905
OREF 126:26891a
TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
IN Vonborstel, Reid W.; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9640165	A1	19961219	WO 1996-US10067	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,				

```
            IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
     IN 177670           A1    19970215    IN 1994-CA701          19940902 <--
     US 5968914          A     19991019    US 1995-472210         19950607 <--
     AU 9661114          A     19961230    AU 1996-61114          19960606
     AU 724805           B2    20000928
     EP 831849           A1    19980401    EP 1996-918461         19960606
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI
     JP 10511689         T     19981110    JP 1997-502184         19960606
     AU 9952624          A     19991202    AU 1999-52624          19991001
     AU 2002320811       A1    20030403    AU 2002-320811         20021223
     AU 2005232288       A1    20051201    AU 2005-232288         20051110
PRAI US 1995-472210      A     19950607
     US 1987-115923      B2    19871028  <--
     US 1987-115929      B2    19871028  <--
     US 1989-438493      B2    19890627  <--
     US 1990-487984      B2    19900205  <--
     US 1991-724340      B2    19910705  <--
     US 1992-903107      B2    19920625  <--
     IN 1992-CA473       A1    19920706  <--
     US 1993-61381       B2    19930514
     US 1993-176485      A2    19931230
     AU 1995-29150       A3    19950630
     WO 1996-US10067     W     19960606
     AU 1999-52624       A3    19991001
     AU 2002-320811      A3    20021223
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G   4     THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 4 OF 9  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Pyrimidine nucleotide precursors for treatment of systemic inflammation
     and inflammatory hepatitis
AB   Pyrimidine nucleotide precursors, including acyl derivs. of cytidine,
     uridine, and orotate, and uridine phosphorylase inhibitors, and their use
     in enhancing resistance to sepsis or systemic inflammation, are disclosed.
     Triacetyluridine improved survival of mice treated with a LD of Salmonella
     typhimurium endotoxin, reduced endotoxin-caused tissue damage, reduced
     mortality in viral hepatitis in mice, and improved recovery from ethanol
     intoxication.
AN   1996:205056  HCAPLUS <<LOGINID::20100301>>
DN   124:250921
OREF 124:46221a,46224a
TI   Pyrimidine nucleotide precursors for treatment of systemic inflammation
     and inflammatory hepatitis
IN   Von Borstel, Reid W.; Bamat, Michael K.; Hiltbrand, Bradley M.
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 95 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 9601115          A1     19960118    WO 1995-US8259         19950630
         W:  AU, CA, CN, JP, KR, MX
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     IN 177670           A1     19970215    IN 1994-CA701          19940902 <--
     US 5691320          A      19971125    US 1995-465454         19950605 <--
     US 6232298          B1     20010515    US 1995-479519         19950607 <--
```

	CA 2193967	A1	19960118	CA 1995-2193967	19950630
	CA 2193967	C	20070911		
	AU 9529150	A	19960125	AU 1995-29150	19950630
	AU 712679	B2	19991111		
	EP 768883	A1	19970423	EP 1995-924764	19950630
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1156409	A	19970806	CN 1995-194806	19950630
	JP 10505578	T	19980602	JP 1996-503935	19950630
	JP 4408450	B2	20100203		
	CN 101066276	A	20071107	CN 2006-10105555	19950630
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	US 20030212036	A1	20031113	US 2003-421831	20030424
	US 20040033981	A1	20040219	US 2003-601863	20030624 <--
	US 20040220134	A1	20041104	US 2004-855835	20040528 <--
	AU 2005232281	A1	20051201	AU 2005-232281	20051110
	AU 2005232286	A1	20051201	AU 2005-232286	20051110
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
	JP 2008007525	A	20080117	JP 2007-250303	20070926
PRAI	US 1994-266897	A	19940701		
	US 1987-115929	B2	19871028	<--	
	US 1989-438493	B2	19890627	<--	
	US 1990-438493	B2	19900626	<--	
	IN 1992-CA473	A1	19920706	<--	
	US 1992-987730	B2	19921208	<--	
	US 1993-158799	B2	19931201		
	US 1995-463740	A1	19950605		
	US 1995-479519	A1	19950607		
	AU 1995-29150	A3	19950630		
	CN 1995-194806	A3	19950630		
	JP 1996-503935	A3	19950630		
	WO 1995-US8259	W	19950630		
	AU 1999-52624	A3	19991001		
	US 2000-702876	A3	20001101		
	AU 2002-320811	A3	20021223		

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents
AB The subject invention discloses compds., compns. and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Effects of other derivs. are also presented. Synthesis of ethoxycarbonyluridine is included.
AN 1995:756200 HCAPLUS <<LOGINID::20100301>>
DN 123:160865
OREF 123:28387a
TI Acylated pyrimidine nucleosides for treatment of toxicity from chemotherapeutic and antiviral agents
IN Von Borstel, Reid Warren; Bamat, Michael Kevin
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426761	A1	19941124	WO 1993-US12689	19931230
	W: AU, CA, JP, KR				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9460812	A	19941212	AU 1994-60812	19931230
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	AU 9952624	A	19991202	AU 1999-52624	19991001
	AU 2002320811	A1	20030403	AU 2002-320811	20021223
	AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI	US 1993-61381	A	19930514		
	IN 1992-CA473	A1	19920706	<--	
	WO 1993-US12689	W	19931230		
	AU 1995-29150	A3	19950630		
	AU 1999-52624	A3	19991001		
	AU 2002-320811	A3	20021223		

OS MARPAT 123:160865
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2010 ACS on STN
TI Preparation and therapeutic used of acylated uridine and cytidine.
GI



AB Acylated pyrimidine nucleosides [I; B = Q where R4 = H; R1, R2, R3 = acyl residue of C5-22 unbranched fatty acid, amino acids (e.g. glycine, L-alanine, and L-lysine), C3-22 dicarboxylic acids, carboxylic acids (e.g. glycolic acid, pyruvic acid, and lactic acid)] (II) and I (B = Q; R1 - R3 = H, acyl radical of a metabolite; R4 = acyl radical of a metabolite] (III) and therapeutic uses of I (B = Q, Q1), e.g. for treating hepatopathies, diabetes, and heart disease, are described. In general, 2',3',5'-tri-O-acyluridines were prepared by heating a solution of 1 g uridine and 3.1 molar equivalent acid anhydride (e.g., Ac2O or butyric anhydride) in anhydrous pyridine at 80-85° for 2 h. A mixture of 2',3',5'-tri-O-acetylcytidine (IV) and -uridine(V) at 590 mg/kg of each administered to rats immediately after, and 1 and 20 h after aorta constriction and administration of isoproterenol (5 mg/kg) significantly restored myocardial performance.
AN 1989:595338 HCAPLUS <<LOGINID::20100301>>
DN 111:195338
OREF 111:32487a,32490a
TI Preparation and therapeutic used of acylated uridine and cytidine.
IN Von Borstel, Reid Warren; Bamat, Michael Kevin
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 8903837	A1	19890505	WO 1988-US3823	19881027	<--
	W: AU, BR, DK, FI, JP, KR, NO, SU, US					
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE					
	AU 8927899	A	19890523	AU 1989-27899	19881027	<--
	EP 339075	A1	19891102	EP 1988-909932	19881027	<--
	EP 339075	B1	19930818			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	JP 02500372	T	19900208	JP 1988-509176	19881027	<--
	JP 2894610	B2	19990524			
	CA 1321994	C	19930907	CA 1988-581429	19881027	<--
	AT 93236	T	19930915	AT 1988-909932	19881027	<--
	JP 10001436	A	19980106	JP 1997-36734	19881027	<--
	JP 3474073	B2	20031208			
	JP 2001192335	A	20010717	JP 2000-379524	19881027	<--
	IN 167680	A1	19901208	IN 1988-MA755	19881028	<--
	IL 88208	A	19961016	IL 1988-88208	19881028	<--
	ZA 8900232	A	19900627	ZA 1989-232	19890111	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	JP 07228535	A	19950829	JP 1994-303877	19941207	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6329350	B1	20011211	US 1995-464939	19950605	<--
	US 7173017	B1	20070206	US 1995-465455	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 20020035086	A1	20020321	US 2001-964514	20010928	<--
	US 7105498	B2	20060912			
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115929	A2	19871028	<--		
	EP 1988-909932	A	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	WO 1988-US3823	A	19881027	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-737913	B3	19910729	<--		
	IN 1992-CA473	A1	19920706	<--		
	US 1992-987730	B2	19921208	<--		
	US 1992-997657	A3	19921230	<--		
	US 1993-158799	B2	19931201			
	US 1994-266897	B3	19940701			
	US 1995-463740	A1	19950605			
	US 1995-466144	A3	19950606			
	AU 1995-29150	A3	19950630			
	AU 1999-52624	A3	19991001			
	AU 2002-320811	A3	20021223			

```
     JP 2005-380457       A3    20051228
OS   MARPAT 111:195338
OSC.G   14    THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
RE.CNT  11    THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8   ANSWER 7 OF 9  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Platinum-dioxopyrimidine complexes
AB   Complexes of 2,4-dioxopyrimidines with cis-diaquodiamineplatinum (II) were
     prepared and tested for antitumor, antibacterial and antiviral activity.
     The complexes appear to have good activity with low renal toxicity.
AN   1984:114992  HCAPLUS <<LOGINID::20100301>>
DN   100:114992
OREF 100:17361a,17364a
TI   Platinum-dioxopyrimidine complexes
IN   Rosenberg, Barnett; Van Camp, Loretta; Ficher, Robert G.; Kansy, Samir;
     Peresie, Henry J.; Davidson, James P.
PA   Research Corp. , USA
SO   U.S., 11 pp. Cont. of U.S. Ser. No. 803,269, abandoned.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 4419351           A     19831206    US 1978-970524         19781218 <--
PRAI US 1974-508854       A1    19740924  <--
     US 1977-803269       A1    19770603  <--
OS   MARPAT 100:114992
OSC.G   7     THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L8   ANSWER 8 OF 9  HCAPLUS  COPYRIGHT 2010 ACS on STN
TI   Platinum-(2,4-dioxopyrimidine) complex
AB   The title complexes were prepared by treating 2,4-dioxopyrimidine derivs.
     with cis-diaquadiammineplatinum(II) [20115-64-4] in a 2:1 to 1:1 mole
     ratio at 0-55°.  The complexes showed antitumor, antiviral, and
     antibacterial activity, high water solubility, and low renal toxicity.  For
     example, 0.01 mole cis-dichlorodiammineplatinum(II) [15663-27-1] was
     treated with 0.02 mole AgNO3 in the dark to give
     cis-diaquadiammineplatinum(II).  This complex was then treated with uracil
     in a 1:1 mole ratio at pH 6-7 to give a complex which showed antitumor,
     antibacterial, and antiviral activity.
AN   1976:428777  HCAPLUS <<LOGINID::20100301>>
DN   85:28777
OREF 85:4645a,4648a
TI   Platinum-(2,4-dioxopyrimidine) complex
IN   Rosenberg, Barnett; Mansy, Samir A. L. A.; Van Camp, Loretta L.; Peresie,
     Henry J.; Fischer, Robert George; Davidson, James P.
PA   Research Corp., USA
SO   Ger. Offen., 51 pp.
     CODEN: GWXXBX
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   DE 2445418           A1    19760401    DE 1974-2445418        19740923 <--
     JP 58028278          B     19830615    JP 1974-112688         19740930 <--
PRAI DE 1974-2445418             19740923  <--

L8   ANSWER 9 OF 9  HCAPLUS  COPYRIGHT 2010 ACS on STN
```

TI Platinum-pyrimidine blues and related complexes. New class of potent antitumor agents

AB Many of the complexes of diaquo species of cis-dichlorodiammineplatinum (II) and pyrimidines and substituted pyrimidines showed superior activity against the ascites Sarcoma 180 tumor in mice when compared to cis-dichlorodiammineplatinum [15663-27-1]. Activity was also shown against the Rauscher leukemia, Ehrlich ascites, and ADJ/PC6A tumors. The platinum-uracil complex caused only minor focal damage to the proximal convoluted tubules of the kidney. The methods for synthesis and characterization of some of the complexes are described, though the structure of the complexes are largely uncertain at this time.

AN 1975:508573 HCAPLUS <<LOGINID::20100301>>

DN 83:108573

OREF 83:16985a,16988a

TI Platinum-pyrimidine blues and related complexes. New class of potent antitumor agents

AU Davidson, James P.; Faber, Paula J.; Fischer, Robert G., Jr.; Mansy, Samir; Peresie, Henry J.; Rosenberg, Barnett; VanCamp, Loretta

CS Dep. Biophys., Michigan State Univ., East Lansing, MI, USA

SO Cancer Chemotherapy Reports, Part 1 (1975), 59(2), 287-300
CODEN: CCROBU; ISSN: 0576-6559

DT Journal

LA English

OSC.G 33 THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)